8.00

3.96% -0.33

After Hours: 8.00

Avadel Pharmaceuticals Plc (AVDL)

Overview News Price History Option Chain Financials Why AVDL Down? Discussions Forecast

Avadel Pharmaceuticals Plc stock is traded at $8.00, with a volume of 869.02K. It is down -3.96% in the last 24 hours and down -25.16% over the past month. Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Previous Close:

$8.33

Open:

$8.33

24h Volume:

869.02K

Relative Volume:

0.57

Market Cap:

$770.89M

Revenue:

$47.56M

Net Income/Loss:

$-156.83M

P/E Ratio:

-4.3716

EPS:

-1.83

Net Cash Flow:

$-127.98M

1W Performance:

+4.03%

1M Performance:

-25.16%

6M Performance:

-51.89%

1Y Performance:

-48.05%

1-Day Range:

$7.93

$8.46

1-Week Range:

$7.59

$8.6278

52-Week Range:

$7.39

$19.09

Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile

Name

Avadel Pharmaceuticals Plc

Sector

Healthcare (1177)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

636-449-1830

Address

BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN

Employee

154

Twitter

@AvadelPharma

Next Earnings Date

2024-12-12

Latest SEC Filings

AVDL's Discussions on Twitter

Compare AVDL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVDL Avadel Pharmaceuticals Plc	8.00	770.89M	47.56M	-156.83M	-127.98M	-1.83
ZTS Zoetis Inc	174.12	78.56B	9.15B	2.43B	2.31B	5.32
TAK Takeda Pharmaceutical Co Adr	13.61	43.15B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	9.51	43.00B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	17.29	19.59B	16.54B	-1.64B	749.00M	-1.45
NBIX Neurocrine Biosciences Inc	150.51	15.24B	2.24B	385.90M	440.10M	3.73

Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-12-24	Initiated	Rodman & Renshaw	Buy
Mar-05-24	Reiterated	H.C. Wainwright	Buy
Mar-05-24	Reiterated	Needham	Buy
Mar-05-24	Reiterated	Oppenheimer	Outperform
Feb-06-24	Initiated	UBS	Buy
Nov-30-22	Upgrade	Jefferies	Hold → Buy
Aug-10-22	Downgrade	Jefferies	Buy → Hold
Jul-28-22	Resumed	Craig Hallum	Buy
May-26-22	Downgrade	Stifel	Buy → Hold
Sep-23-21	Initiated	Needham	Buy
Jul-31-20	Initiated	Oppenheimer	Outperform
Jul-21-20	Initiated	SVB Leerink	Outperform
Jun-30-20	Initiated	H.C. Wainwright	Buy
Apr-03-20	Initiated	Jefferies	Buy
Mar-12-20	Initiated	Stifel	Buy
Feb-26-20	Initiated	Piper Sandler	Overweight
Jan-30-20	Initiated	Craig Hallum	Buy
Jun-14-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Feb-08-19	Downgrade	Ladenburg Thalmann	Buy → Neutral

View All

Avadel Pharmaceuticals Plc Stock (AVDL) Latest News

Feb 06, 2025

Quarterly Snapshot: Quick and Current Ratios for Avadel Pharmaceuticals plc (AVDL) - The Dwinnex

Feb 06, 2025

Examining Avadel Pharmaceuticals plc (AVDL) more closely is necessary - US Post News

Feb 06, 2025

Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World

Feb 06, 2025

Feb 04, 2025

Investors in cash trouble should check out Avadel Pharmaceuticals plc (AVDL) - SETE News

Feb 04, 2025

How the (AVDL) price action is used to our Advantage - Stock Traders Daily

Feb 04, 2025